Saturday, January 25, 2025

CATEGORY

Partnership

Johnson & Johnson Expands Neuroscience Portfolio by Acquiring Intra-Cellular Therapies

Johnson & Johnson has solidified its position in the neuroscience sector through the acquisition of Intra-Cellular Therapies, a move that brings to its expansive...

Cytovance and PolyPeptide Unite to Accelerate Peptide Drug Innovations

Cytovance Biologics partners with PolyPeptide to deliver comprehensive solutions for peptide drug development, catering to the increasing industry demand with enhanced production capabilities and...

J&J Acquires Intra-Cellular Therapies for $14.6 Billion, Strengthening Neuroscience Portfolio

New Brunswick, N.J. and Bedminster, N.J., January 13, 2025 – Johnson & Johnson has finalized the acquisition of Intra-Cellular Therapies, Inc. for $132.00 per...

GSK Acquires IDRx to Expand GIST Treatment Options

GSK plc has solidified its commitment to advancing gastrointestinal stromal tumor (GIST) therapies by finalizing the acquisition of Boston-based IDRx, Inc. This strategic move...

Eckert & Ziegler, GlyTherix Expand Partnership with Actinium-225 Agreement

Eckert & Ziegler SE and GlyTherix Ltd have significantly broadened their collaborative efforts by finalizing a global supply agreement for Actinium-225, enhancing their joint...

Eckert & Ziegler Partners with GlyTherix to Supply Actinium-225 for Cancer Treatment

Eckert & Ziegler SE, a leader in isotope-related components, has expanded its collaboration with GlyTherix Ltd, an Australian radiotherapy innovator. The partnership now includes...

Gilead and LEO Pharma Team Up to Develop Oral STAT6 Treatments for Inflammatory Diseases

Gilead Sciences and LEO Pharma have announced a strategic partnership focused on accelerating the development and commercialization of oral STAT6 inhibitors. This collaboration targets...

Royalty Pharma Projects $2.8 Billion in 2024 Portfolio Receipts

Royalty Pharma plc has announced a robust financial outlook for the year 2024, anticipating Portfolio Receipts to reach approximately $2.8 billion. This projection aligns...

Zai Lab Partners with Vertex to Launch Pove in Asian Markets

Zai Lab Limited and Vertex Pharmaceuticals Incorporated have forged an exclusive partnership to develop and bring povetacicept, a promising therapeutic, to patients across mainland...

Pacira Launches 5×30 Growth Plan, Reports $701M Revenue for 2024

Pacira BioSciences, Inc. has announced an ambitious five-year strategy aimed at solidifying its position as a leader in non-opioid pain management. The company revealed...

SYNEKTIK Czech Republic Deploys Advanced da Vinci Surgical Robots at Olomouc University Hospital in €16.4M Deal

SYNEKTIK Czech Republic has secured a major contract with Olomouc University Hospital to enhance its surgical capabilities through the integration of the da Vinci...

Zai Lab Joins Forces with MediLink to Advance Cancer Drug ZL-6201

Zai Lab Limited has announced a strategic collaboration with MediLink Therapeutics, aiming to develop ZL-6201, a novel antibody-drug conjugate (ADC) targeting LRRC15. This partnership...

Madagascar Boosts COVID Vaccine Uptake with Community-Driven Strategy

In the Boeny region of Madagascar, a tailored COVID-19 vaccination campaign successfully administered nearly 25,000 vaccines over six months by implementing a community-focused approach....

HERA Launches Stakeholders Hub Enhancing EU Pharma Collaboration

The Health Emergency Preparedness and Response Authority (HERA) today introduced the Stakeholders Hub, a comprehensive platform designed to strengthen cooperation across the European Union's...

Coave Therapeutics Raises $33 Million Series A to Propel Genetic Medicine Innovations

Paris-based Coave Therapeutics has successfully secured $33 million in a Series A funding round aimed at advancing its groundbreaking work in genetic medicines. This...

Latest news